Headline
The latest stories from AHA Today.
The Centers for Medicare & Medicaid Services issued an interim final rule that, among other provisions, makes collecting and reporting COVID-19-data a condition of participation for hospitals that participate in Medicare.
Associations Now, the American Society of Association Executives鈥 magazine for nonprofit professionals, has named AHA to its list of 鈥100 Associations That Will Save the World.鈥
The Democratic Republic of the Congo has reported 100 confirmed or probable Ebola cases and 43 deaths in Equateur Province since June 1, the World Health Organization reported.
The AHA urged the Centers for Medicare & Medicaid Services to reverse its calendar year 2021 Home Health Prospective Payment System Rate Update of 4.36% behavioral offset for the remainder of CY 2020 and beyond until all CY 2020 data are available for analysis.
Island child care programs reported just 52 confirmed or probable COVID-19 cases after reopening in June and July, according to a report released by the Centers for Disease Control and Prevention.
An updated AHA resource examines the impact of the social determinants of health on patients and communities as they battle the COVID-19 public health emergency.
AHA Board Chair Melinda Estes, M.D., will be joined by Rachelle Schultz, president and CEO of Winona Health, for the next in a series of Leadership Rounds 鈥 short conversations on a range of key issues Dr. Estes will have with hospital and health system leaders from across the country.
The Food and Drug Administration issued an emergency use authorization for investigational convalescent plasma to treat suspected or laboratory-confirmed COVID-19 in hospitalized patients.
The Centers for Medicare & Medicaid Services, departments of Housing and Urban Development and Agriculture, Administration for Community Living, Centers for Disease Control and Prevention, and Health Resources and Services Administration released a joint informational bulletin to help states鈥
In an effort to reduce regulatory burden, the Food and Drug Administration will not require developers to submit a premarket approval application, premarket notification or emergency use authorization for laboratory developed tests, the Department of Health and Human Services announced this week.